insights_auto
Why is CRSP down 3,45%?
Dive Deeperchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
51,55 $
arrow_downward
-3,45%(-1,84) 1D
51,51 $
arrow_downward
-0,08% (-0,040)bedtimeAfter hours
Closed: 12 հոկ, 16:00:02 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
52,91 $
High
53,21 $
Low
51,40 $
Mkt. cap
4,98 մլրդ
Avg. vol.
1,63 մլն
Volume
0,00
52-wk high
75,16 $
52-wk low
44,12 $
EPS
-4,76 $
Beta
1,45
Shares outstanding
96,69 մլն
No. of employees
393
Open
52,91 $
High
53,21 $
Low
51,40 $
Mkt. cap
4,98 մլրդ
Avg. vol.
1,63 մլն
Volume
0,00
52-wk high
75,16 $
52-wk low
44,12 $
EPS
-4,76 $
Beta
1,45
Shares outstanding
96,69 մլն
No. of employees
393
News stories
From web sources and news partners
Yahoo Finance Australia
·
9 ժամ առաջ
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
Zacks
·
14 ժամ առաջ
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
Zacks
·
15 ժամ առաջ
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG